Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Roudy who wrote (1669)	7/14/1999 3:32:00 PM
From: Maurice Winn	1 Recommendation Respond to of 1762

Off-Label Use of Rituxan The Lehman report said that 30% of applications are off-label. Do you know what those off-label applications are Don? Meanwhile, IDEC reached $91 briefly today. That's quite a rise from $2 a few years ago. Market Capitalization of $1.8bn according to Yahoo! gives them some serious grunt to expand their lymphoma treatment position. <...collaboration between IDEC and Genentech achieved U.S. net sales of Rituxan® (Rituximab) totaling $68.3 million for the three months ending June 30, 1999. ................licensing fee from Schering AG for the exclusive ex-U.S. marketing and distribution rights to ZEVALIN(TM).....> Sales of Rituxan running at $300m per year at present. Per treatment $6000 [but that's from a poor memory] so about 50,000 people per year are being treated [give or take a few retreatments and maybe the price is a bit higher and maybe there are a lot of free treatments under IDEC's help-the-poor scheme where a proportion of sales are given in needy cases, again just my fuzzy memory]. Zevalin will do a lot better than Rituxan since it will not only identify the cells for immune system destruction but will nuke a large proportion of them too. Yayyy for the people at IDEC. I hope you are enjoying your achievement. How about buying Techniclone and getting things moving really fast on Oncolym and getting on with the surgery/CHOP/Rituxan/Oncolym combined treatment testing which is sorely lacking for CD20 positive people. Don't forget to add cod liver oil [Vitamin D and Vitamin A] as well as cell repair nutrients so that people's nutrient levels are at their best during and after treatment. Maurice

To: Roudy who wrote (1669)	7/14/1999 4:02:00 PM
From: Maurice Winn	1 Recommendation Read Replies (2) \| Respond to of 1762

Incidentally, you might recall over a year ago I reported that a doctor at Scripps Clinic told me he had treated people with Rituxan [this was before February 1998] and had had a couple of cases of tuberculosis from it. I'm interested in the infections resulting from the B-cell depletion Rituxan causes. He also said that in a few years, tuberculosis was likely to become a serious threat with treatment options limited. This antibiotic immunity has been widely reported, but I haven't seen much worry about widespread epidemics of tuberculosis. Have there been reports on these or was this doctor exaggerating about tuberculosis and Rituxan for some reason [perhaps to justify in my mind why he was not offering Rituxan for a CD20 positive intermediate grade NHL]? All I have seen are the boring old reports of people feeling as though they have a bit of influenza. I recall some time that there were some serious side-effects with treatment stopped in some cases. The side-effects would be interesting. Is there a url? Maurice